EB-DT-CAR-NK(CLDN18.2/HER2) Drug Due Diligence Report 2026

This EB-DT-CAR-NK(CLDN18.2/HER2) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether EB-DT-CAR-NK(CLDN18.2/HER2) can convert its CAR-NK profile and CLDN18.2 x HER2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	EB-DT-CAR-NK(CLDN18.2/HER2) (query alias: EB-DT-CAR-NK(CLDN18.2/HER2))
Modality / target	CAR-NK; CLDN18.2 x HER2; CLDN18.2 modulators, HER2 modulators
Highest global status	Phase 1/2
Originator	Beijing Biotech
Active developers	Beijing Biotech

The MCP disease footprint includes Adenocarcinoma of Esophagus, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07622940	Phase 1/2	Recruiting	36	Primary endpoint not disclosed in English source
NCT07551362	Phase 1/2	Recruiting	36	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

EB-DT-CAR-NK(CLDN18.2/HER2) addresses Adenocarcinoma of Esophagus, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—CAR-NK—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 34 matched transaction record(s) under the scope “target-level comparable: CLDN18.2 x HER2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CLDN18.2 x HER2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-03-05	Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal	Phase 1	US$169.7M upfront; US$1,235.5M milestones; US$1,500.6M stated total
2025-10-21	Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Generation Investigational Oncology Medicines	Phase 3	US$1,200.0M stated total
2025-08-28	ImmuneOncia signs MOU with IMBDx to accelerate cancer drug and precision medicine development	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Cytokine-release syndrome, neurotoxicity, infection, and treatment logistics
Durability of response and antigen escape
Manufacturing scalability, release testing, and site readiness

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION